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non-Hodgkin lymphoma, colorectal cancer (CRC), urothelial 
carcinoma, cholangiocellular carcinoma (CCC) and prostate 
cancer. The most common tumour type in Crohn’s disease 
patients (13/22) was lymphoma (5 cases), in ulcerative colitis 
patients (9/22) CCC (2 cases) and CRC (2 cases). The observed 
incidence of lymphoma (32.5/100,000), bladder carcinoma 
(21.7/100,000) and CCC (10.8/100,000) was higher than ex-
pected and known from general population. All of the pa-
tients that developed a malignancy had received immuno-
suppressive therapy. Compared to a cohort of 927 IBD pa-
tients without malignancies there were no statistical 
differences regarding gender, antibodies targeting tumour 
necrosis factor and thiopurine use.  Conclusion: Our data 
support the assumption that a long-standing disease course 
and immunosuppressive therapy increase the risk for devel-
oping malignancies in IBD patients.  © 2016 S. Karger AG, Basel 
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 Abstract 
 Background: Gastrointestinal and extraintestinal malignan-
cies are long-term complications in patients with inflamma-
tory bowel disease (IBD), likely as a result of chronic inflam-
mation and the use of immunosuppressive medications 
used to control inflammation. Here, we assessed the fre-
quency of malignancies in a large tertiary IBD centre at the 
University Hospital Zurich.  Methods: We performed a retro-
spective analysis of data from 1,026 patients from our IBD 
clinic treated between 2007 and 2014.  Results: Twenty two 
of the 1,026 patients developed 28 cases of malignancies, 14 
patients were male and 8 patients female. The median la-
tency between IBD diagnosis and first malignancy was 13 
years (range 2–27 years). Most common malignancies were 
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 Introduction 
 Patients suffering from inflammatory bowel disease 
(IBD) have an increased risk for developing intestinal and 
extra-intestinal neoplasia, as compared to the general 
population  [1–3] . An important pathogenetic risk factor 
is considered to be the chronic ongoing inflammation re-
sulting in tissue destruction and remodelling  [4, 5] . In 
addition, there is good evidence that immunosuppressive 
drugs used to control the inflammation in IBD patients, 
such as purine antimetabolites (azathioprine (AZA)/6-
mercaptopurine (6-MP)) or monoclonal antibodies tar-
geting tumour necrosis factor (anti-TNF) also increase 
the risk for the development of certain cancers, such as 
non-Hodgkin lymphoma (NHL), non-melanoma skin 
cancer or melanoma  [6, 7] . The increased risk of lympho-
ma and skin cancer is associated with the use of thiopu-
rines  [8] . In general, some malignancies occur more often 
newly or recurrently in IBD patients  [9] . A recent meta-
analysis showed that IBD patients taking thiopurines are 
at an increased risk for developing NHL  [10] . A nation-
wide French prospective observational study (CESAME) 
demonstrated that patients receiving thiopurines were at 
an increased risk for developing lymphoproliferative dis-
orders  [11] . The increased risk of lymphoma is higher in 
patients with Crohn’s disease (CD), whereas patients with 
both ulcerative colitis (UC) and CD are at an increased 
risk of developing leukaemia  [4, 12, 13] .
 With respect to the basic risk of developing malignan-
cies in IBD, there are conflicting results. A Finnish study 
patients with UC were found to have an increased risk of 
colon, rectal, biliary tract, and thyroid cancers, and the 
risk of colorectal cancer (CRC) was highest among the 
youngest UC patients. Patients with CD had a significant-
ly increased risk for cancers of the small intestine, anus, 
and biliary tract, and also for myeloma. In addition, the 
risk of basal cell skin cancer was increased in IBD  [14] . In 
contrast, data from Denmark indicated that only CD pa-
tients had an increased risk of developing malignancies 
overall, such as small bowel cancer, lung cancer or NHL, 
while the general risk for developing cancer in UC pa-
tients was not increased  [15] . A large population-based 
study from Danish health care databases found that pa-
tients with IBD, particularly CD, were at an increased risk 
for gastrointestinal and extraintestinal malignancies  [16] .
 These reports indicate that there might be population-
dependent differences in the risk for developing malig-
nancies in IBD patients. Furthermore, the risk for IBD 
patients to develop cancer certainly also depends on indi-
vidual factors, such as age, disease phenotype (CD vs. 
UC), IBD-related medications and disease duration. 
Thus, the composition of patient cohorts influences the 
overall outcome with respect to malignancies. Further, 
incidence ratios within cohorts are influenced by the re-
cruitment location (i.e. single tertiary referral centre vs. 
population-based study).
 As also discussed at a recent ECCO guideline confer-
ence on malignancies in IBD, more data on this topic are 
certainly required. Therefore, we screened the medical 
charts of 1,026 patients from the large IBD clinic of the 
University Hospital of Zurich for the incidence of malig-
nancies after the diagnosis of IBD. A systematic clinical 
analysis of features and characteristics of these malignan-
cies was performed.
 Patients and Methods 
 We retrospectively screened the charts of 1,026 patients from 
the IBD clinic at the University Hospital of Zurich seen between 
2007 and 2014. The study was approved by the local Ethical Com-
mittee (IRB approval number: EK-1316 by the Cantonal Ethics 
Committee of the Canton Zürich, Switzerland).
 We reviewed patients’ medical records regarding demograph-
ics (age at diagnosis, sex), disease characteristics of their IBD, such 
as type and course of disease and treatment (type of IBD, compli-
cations as fistula and/or bowel stenosis, history of surgery, history 
of medical therapy), and data regarding any malignancies (latency 
between diagnosis of IBD and occurrence of malignancy, includ-
ing entity, stage and its treatment). A descriptive statistical analysis 
was performed. Qualitative variables were expressed as percent-
ages, whereas quantitative variables as median. For the statistical 
analysis, Fisher’s exact test was performed (Prism 5.04 for Win-
dows, GraphPad Software Inc., La Jolla, Calif., USA). The tumour 
incidence was calculated by using the earliest tumour diagnosis 
year (1996) as the baseline, and then calculating the yearly inci-
dence of tumours in the total IBD cohort in the period of time un-
til 2014 (over a time period of 18 years). We compared our data 
with the data published by the National Institute for Cancer Epi-
demiology and Registration (NICER) collecting cancer-specific 
data in Switzerland. As a control cohort, we used data from 927 
patients from our IBD clinic who did not develop malignancy.
 Results 
 Demographic Aspects 
 Out of 1,026 patients from our IBD clinic enrolled in 
our data search, we identified 22 (2.1%) patients (13 
(59%) with CD; 9 (41%) with UC), who developed any 
malignancy after diagnosis of IBD. The median age at 
data acquisition was 56 (range 21–85 years). The median 
age at the diagnosis of IBD was 30 (range 11–66 years), 
whereas the median latency between IBD diagnosis and 
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the onset of the first malignancy was 13 years (range 2–27 
years). The majority of patients were male (14, 64%, 
7 with CD, 7 with UC). The median age at diagnosis of 
the malignancy of the male patients was 33 (range 12–66 
years). Eight (36%) IBD patients who developed a malig-
nancy were female with a median age of 30 (range 11–63 
years) at diagnosis of IBD, of which 6 (75%) displayed CD 
and 2 (25%) UC. Further details can be found in  tables 1 
and  2 .
 In the cohort of 927 IBD patients who did not de-
velop malignancy 540 had CD (58%), 320 UC (35%) and 
67 indeterminate colitis (7%). Four hundred and forty 
eight were female (48%) and 479 male (52%). The me-
dian age at data acquisition was 45 years (range 19–102 
years). There was no statistical difference comparing 
the genders (p = 0.2888) and disease types (CD vs. UC; 
p = 0.8240) between the patient group that developed 
malignancy and the cohort that did not develop malig-
nancy.
 Occurrence of Malignancies 
 The identified 22 patients developed 28 cases of malig-
nancy.  Table 3 shows the comprehensive list of malignan-
cies, the distribution of tumour types and type of IBD in 
details. NHL was developed by 5 patients (4 CD, 1 UC, 
18% of the malignancies, one of the NHL was a hepato-
splenic T-cell lymphoma (HSTCL) by a CD patient), CRC 
by 4 patients (2 CD, 2 UC, 14% of the malignancies), uro-
thelial carcinoma by 3 patients (2 CD, 1 UC 11% of the 
malignancies), cholangiocellular carcinoma (CCC) by 
2 patients (2 UC, 7% of the malignancies), malignant mel-
anoma by 1 patient (UC, 4% of the malignancies), Hodg-
kin’s lymphoma by 1 patient (CD, 4% of the malignan-
cies). From the 2 UC patients who developed CCC, 1 pa-
tient had a suspected PSC (patient number 21). Out of the 
6 patients who developed lymphoma (NHL including 
HSTCL and Hodgkin’s disease) one was treated with 
thiopurines alone, one was treated with a combination of 
thiopurines and anti-TNF antibodies, 2 were treated with 
anti-TNF antibodies alone, and one with steroids only. 
For the remaining patient, no sufficient data about his 
previous therapy were available. Of note the smoking sta-
tus regarding the patients with urothelial carcinoma 
could not be retrieved.
 We calculated the incidence for the most frequent tu-
mours. For lymphoma (NHL and Hodgkin’s lymphoma 
combined), an incidence rate of 32.5/100,000 was calcu-
lated, for NHL alone 27/100,000, and for Hodgkin’s 
 lymphoma 5.4/100,000. For CRC, in our patient cohort 
an incidence rate of 21.7/100,000 was calculated. The 
 incidence rate of bladder carcinoma was 21.7/100,000, 
of  CCC 10.8/100,000, and of malignant melanoma 
5.4/100,000 ( table 4 ).
 IBD-Specific Medication 
 Two of the 22 patients received mesalazine as IBD-
specific medication. Seven patients received AZA, 2 pa-
tients received 6-MP, 5 patients methotrexate, 4 patients 
adalimumab (ADA), 8 patients infliximab (IFX), and 
1  patient certolizumab pegol (CZP). Details regarding 
medication are shown in  table  1 . Anti-TNF antibodies 
(ADA, IFX, CZP) were applied to 9 (41%) patients. Eight 
of those 9 patients (89%) with anti-TNF antibodies had a 
co-medication. For 4 out of 22 identified patients, no suf-
ficient data on IBD-specific immunosuppressive therapy 
were available ( table 1 ).
 In the IBD population without malignancies, 220 of 
927 patients received anti-TNF treatment (ADA, IFX, 
CZP, previous or concurrent AZA treatment included) 
(24%), 126 had anti-TNF treatment with no previous or 
concurrent AZA treatment (14%). Two hundred and 
fourteen had AZA treatment (37%), 120 with no previous 
or concurrent anti-TNF treatment (13%).
 When comparing the malignoma patients with this 
cohort, there was no statistical difference regarding anti-
TNF, with and without concurrent or past AZA treat-
ment (p  = 0.0766 and p  = 0.2124, respectively), AZA 
treatment, with and without concurrent or past anti-TNF 
treatment (p = 0.3169 and p = 0.7571, respectively).
 Discussion 
 In our IBD clinic with a large collective of 1,026 pa-
tients, 22 (2.1%) patients developed a malignancy over a 
time course of 7 years (2007–2014). The median latency 
between IBD diagnosis and occurrence of malignancy 
was 13 years. Of note, CCC was the earliest diagnosed tu-
mour, with a mean latency of 13.5 years. The mean age of 
patients at diagnosis of malignancy was 59.5, similar to 
data in the literature (56.2 years  [17] ).
 Lymphomas were the most frequent malignancies 
within our IBD cohort, making up 6 (21%) of all malig-
nancies. The incidence of lymphoma in the IBD cohort 
was estimated to be 32.5/100,000, for NHL 27/100,000, 
and for Hodgkin lymphoma 5.4/100,000. The incidence 
rates (related to 100,000) of lymphoma in the general 
Swiss population, published by the Foundation NICER, 
were lower (Hodgkin lymphoma: 3.7 (males), 2.5 (fe-
males); NHL: 16.9 (males), 11.7 (females))  [18] . The 
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CESAME study group found a similar incidence for lym-
phoma (related to 100,000) in French IBD patients 
(26/100,000 in patients discontinuing thiopurines, 
20/100,000 for patients who never assumed thiopurins) 
 [11] . Our results confirm that the incidence of lymphoma 
in IBD patients is higher than in the general population 
and is in line with other studies  [10, 19] . An association 
between thiopurines (AZA, 6-MP, TG) and lymphoma 
(especially NHL) is described in the literature  [11, 20] . In 
our cohort, 2 patients received thiopurines, 3 patients an-
ti-TNF antibodies, and 1 patient both thiopurines and 
anti-TNF antibodies. Due to the small sample size of pa-
tients in our cohort, it is difficult to assess a link between 
medication and lymphoma. Our data suggest that lym-
phomas are more common in patients with CD than UC 
patients, in males rather than in females, and occur more 
frequently than in the general Swiss population. These 
findings are in line with available literature from other 
countries  [21, 22] .
 CRC was the second most common malignancy in our 
IBD patients, making up 14% of all cancers. We estimated 
an incidence of 21.7/100,000, which is lower than the in-
cidence in the general Swiss population (NICER, 47.7 for 
males, 29.5/100,000 for females). Similar results were 
achieved by a recent Spanish cohort study  [23] . This par-
adoxical result is most likely caused by the fact that the 
median age of the investigated population was quite low 
and the incidence of CRC increases with age. Another 
reason for the low incidence may be our strict regular en-
doscopic screening of IBD patients, which may prevent 
the occurrence of CRCs  [24, 25] . This decreasing trend 
was also confirmed by other recent studies  [25, 26] .
 Bladder carcinoma was the third most frequent can-
cer. All the patients were male, with an estimated inci-
Characteristics Number of patients, %
Total patients, n (%) 22 (100)
Type of IBD
CD 13 (59)
UC 9 (41)
Gender
Male 14 (64)
Female 8 (36)
Age at IBD diagnosis, years, median (range) 30 (11–66)
Complications of CD
Fistula 7 (54)
Bowel stenosis 6 (46)
History of IBD-related surgery
CD patients 8 (57)
UC patients 2 (16)
Latency between IBD and first tumor diagnosis, years 13 (2–37)
Table 3.  Summary of malignancies developed by IBD patients
Disease, n  Total numbers and type of malignancies
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CD 1 2* 2 1 1 1 3 1 1 1 1
UC 1 2 2 2 1 1 1 1 1 1
Total (n = 28), n (%) 1 (4) 3 (11) 1 (4) 2 (7) 4 (14) 1 (4) 1 (4) 1 (4) 1 (4) 1 (4) 1 (4) 1 (4) 4 (14) 1 (4) 1 (4) 2 (4) 1 (4)
 HCC = Hepatocellular carcinoma. * The second event represents a relapse.
Table 2.  Demographic characteristics of 22 
IBD patients with malignancies after diag-
nosis of IBD, from our IBD outpatient clin-
ic with 1,026 patients
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dence of 21.7/100,000. The NICER data indicate an in-
cidence of 16.7/100,000 for males. Our data are consis-
tent with studies in others populations  [4, 27, 28] . 
Especially, a recent publication by Beaugerie and Itz-
kowitz  [1] pointed to the higher incidence of urothelial 
cancers in patients taking thiopurines, but not anti-TNF 
alpha antibodies. CCC occurred in our cohort only in 
UC patients with an estimated incidence of 10.8/100,000. 
Data from the general population indicate an incidence 
of 2.9/100,000 for males and 2.5/100,000 for females. An 
Table 4.  Representation of the 22 patients with the corresponding latency in years (first column) until development of malignancies af-
ter the first diagnosis of IBD
Patient number Latency occurrence of
malignancy after
diagnosis of IBD, years 
Type(s) of malignancy Cancer stage
1 26.4 Prostate 
Bladder
n.d. 
G1pTa
2 18.3 HCC NHL n.d. III
3 19.3 Breast (recurrent disease) pT2, pN0, M0, G1
4 25 Colorectal T2, ypN0 (0.14)
5 3 Small bowel pT4, pN1
6 22 HSTCL IV
7 23 Hodgkin lymphoma IIIB
8 27.3 Bladder 
GIST
n.d. 
pT1a, G2, L1
9 12 Colorectal pT3, pN2, G3, L1, V1
10 18 Pancreas pT3, pN1 (5/19), cM02, G2, L1
11 4 NHL IVA
12 9 Leukemia n.d.
13 37 NHL IVBE
14 4 Bladder pTa low grade
15 11 Prostate T1c, Nx, M0, Gleason6
16 5
5
Basal cell carcinoma 
NHL
n.d.
17 12 Esophagus pT1, pN0, cM0, G2
18 2 Cholangiocellular pT3, pN1 (10/46), L1, V1, Pn1, G2, M0, R0
19 13 Melanoma pT1a, N0, M0
20 9 Colorectal pT3, pN2b (23/39), G3, L1, V1
21 25.6 Cholangiocellular 
Colorectal
n.d. 
n.d.
22 n.d. Mesothelioma cT3/T4 cN0, cM0
Median latency until first 
malignancy, years
13 (2–37)
 The third column represents the malignancy type (s), and the fourth the histological cancer stage (in TNM, Ann-Arbor). n.d. = No 
data.
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incidence of 8.2/100,000 has been reported in a Danish 
cohort study for UC patients  [17] . In our study, there is 
a much higher rate in UC patients, in line with literature 
data  [4, 17] . The risk for CCC in UC patients is mainly 
caused by primary sclerosing cholangitis PSC  [29] as 
confirmed in our cohort. The incidence of malignant 
melanoma was estimated to be 5.4/100,000, whereas 
NICER data suggested an incidence of 26.4 for males 
and 23.3/100,000 for females in Switzerland. The low 
incidence is in contrast with most of the population-
based studies  [4, 14, 30] . However, the CESAME cohort 
study found an incidence similar to the general popula-
tion  [31] . Algaba et al.  [23] also confirmed this new 
trend. The suggested regular skin cancer screening in 
IBD patients may be the reason for this finding. HSTCL 
is a rare disorder, and only 200 cases were reported 
worldwide in the literature  [32, 33] . Our case was con-
sistent with literature cases  [34–36] , who showed the 
typical constellation (relatively young man (41 years)) 
with longstanding CD who developed HSTCL after as-
suming 6-MP and IFX.
 Taken together, our data suggest that lymphoma (es-
pecially NHL), urothelial carcinoma and CCC are more 
common in IBD patients than in the general Swiss popu-
lation.
 Certainly this study has several limitations. We pre-
sented the data from only 1,026 IBD patients retrospec-
tively. Patients were recruited in a tertiary referral centre 
for IBD. In Switzerland, patients with mild or moderate 
disease are usually managed by general practitioners or 
private practice gastroenterologists. Only patients with 
severe disease are usually seen at referral centers. There-
fore, patients with mild disease are underrepresented in 
this study and the findings might therefore be biased to-
wards more severe disease courses. Additionally, not all 
patients were initially diagnosed with IBD at our clinic 
but were seen after a major event within the course of 
IBD. Therefore, some data regarding medication, cancer 
stage and in some cases latency until occurrence of can-
cer are incomplete. However, more severe disease is more 
likely to be treated with immunosuppressive agents and 
may thus be more prone to the development of malig-
nancies. This would mean that our data overestimate the 
risk of malignancies and their incidence as compared to 
a desirable Swiss population-based study. Population-
based studies certainly come closer to the ‘true incidence’ 
of malignancies in IBD patients. However, the patients at 
highest risk are seen in referral centres. Therefore, we be-
lieve that our data are of value especially for those cen-
ters.
 In summary, our data indicate that the onset of malig-
nancy in IBD patients is associated with a long-standing 
disease course of IBD, but also with the use of immuno-
suppressive medication. Our data are in line with the lit-
erature. However, the incidence rates are lower than ex-
pected. Of note is the relatively high incidence of urothe-
lial carcinoma supporting recent findings from the 
CESAME cohort. The risk for this tumor entity has so far 
been overlooked and further studies to evaluate a place 
for surveillance programs for urothelial cancer in IBD pa-
tients are warranted.
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